JustWire.io

Mon, 24.08.2026 Daiichi Sankyo

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the compa...

Newsfeed

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio | Daiichi Sankyo Co., Ltd.

Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results | Daiichi Sankyo Co., Ltd.

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy | Daiichi Sankyo Co., Ltd.

Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer | Daiichi Sankyo Co., Ltd.

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors | Daiichi Sankyo Co., Ltd.

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026 | Daiichi Sankyo Co., Ltd.

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates | Daiichi Sankyo Co., Ltd.

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors | Daiichi Sankyo Co., Ltd.

Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation | Daiichi Sankyo Co., Ltd.

Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies | Daiichi Sankyo Co., Ltd.

Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | Daiichi Sankyo Co., Ltd.

Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program | Daiichi Sankyo Co., Ltd.

ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D | Daiichi Sankyo Co., Ltd.

ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer | Daiichi Sankyo Co., Ltd.

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo | Daiichi Sankyo Co., Ltd.

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology | Daiichi Sankyo Co., Ltd.

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer | Daiichi Sankyo Co., Ltd.

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe | Daiichi Sankyo Co., Ltd.

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer | Daiichi Sankyo Co., Ltd.

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer | Daiichi Sankyo Co., Ltd.

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy | Daiichi Sankyo Co., Ltd.

ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer | Daiichi Sankyo Co., Ltd.

DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS | Daiichi Sankyo Co., Ltd.

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen | Daiichi Sankyo Co., Ltd.

General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform | Daiichi Sankyo Co., Ltd.

DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo | Daiichi Sankyo Co., Ltd.

DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer | Daiichi Sankyo Co., Ltd.

DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial | Daiichi Sankyo Co., Ltd.

DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02 | Daiichi Sankyo Co., Ltd.

ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial | Daiichi Sankyo Co., Ltd.

ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial | Daiichi Sankyo Co., Ltd.

DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial | Daiichi Sankyo Co., Ltd.

DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02 | Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Establishes Third Research Institute in San Diego | Daiichi Sankyo Co., Ltd.

ENHERTU® Followed by THP Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer Prior to Surgery | Daiichi Sankyo Co., Ltd.

XFRA: DIVIDEND/INTEREST INFORMATION - 29.09.2025 - JP3475350009 | Daiichi Sankyo Co., Ltd.

ENHERTU® Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer | Daiichi Sankyo Co., Ltd.